Scholarlink

<p>Friedreich’s ataxia (FRDA) is the most common early onset hereditary ataxia, caused by GAA repeat expansions in the <i>FXN</i> gene. The length of the shorter allele (GAA1) and age at onset are established determinants of disease severity, though additional biomarkers such as frataxin expression and neurofilament light chain (NfL) have been proposed. We conducted a 30-month prospective longitudinal study, including 25 FRDA patients and 16 heterozygous carriers, assessing clinical progression through SARA, FARS–ADL, INAS, EQ-5D, SCAFI, and CCFS scales. Baseline measures included GAA repeats, frataxin expression in fibroblasts, CSF NfL, and disease burden. Frataxin levels were significantly reduced in patients and correlated with GAA1 length and baseline severity. SARA, FARS–ADL, and INAS worsened significantly over time, while SCAFI and CCFS remained stable. GAA1 length and baseline SARA score emerged as the strongest predictors of progression. CSF NfL was elevated in younger patients and declined with age but did not correlate with severity or progression. These results support GAA1 length and baseline clinical status as robust predictors of progression and suggest limited utility of CSF NfL as a longitudinal biomarker particularly in later disease stages.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Longitudinal analysis shows GAA1 length and baseline clinical status as robust predictors of progression in Friedreich ataxia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月9日

查看全文
  • Leire Manrique,
  • Francisco Martínez-Dubarbie,
  • Ana L. Pelayo-Negro,
  • Natalia Benitez-Calle,
  • María Victoria Sanchez-Pelaez,
  • Daniel Cota-Gonzalez,
  • Ruben Loza,
  • Raquel Martinez-Díaz,
  • Juan Irure-Ventura,
  • Coro Sanchez-Quintana,
  • Ivelisse Sanchez,
  • Antoni Matilla-Dueñas,
  • Jon Infante

摘要

Friedreich’s ataxia (FRDA) is the most common early onset hereditary ataxia, caused by GAA repeat expansions in the FXN gene. The length of the shorter allele (GAA1) and age at onset are established determinants of disease severity, though additional biomarkers such as frataxin expression and neurofilament light chain (NfL) have been proposed. We conducted a 30-month prospective longitudinal study, including 25 FRDA patients and 16 heterozygous carriers, assessing clinical progression through SARA, FARS–ADL, INAS, EQ-5D, SCAFI, and CCFS scales. Baseline measures included GAA repeats, frataxin expression in fibroblasts, CSF NfL, and disease burden. Frataxin levels were significantly reduced in patients and correlated with GAA1 length and baseline severity. SARA, FARS–ADL, and INAS worsened significantly over time, while SCAFI and CCFS remained stable. GAA1 length and baseline SARA score emerged as the strongest predictors of progression. CSF NfL was elevated in younger patients and declined with age but did not correlate with severity or progression. These results support GAA1 length and baseline clinical status as robust predictors of progression and suggest limited utility of CSF NfL as a longitudinal biomarker particularly in later disease stages.